Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cutaneous melanoma].

T K Eigentler1, L-O Mügge, A Bembenek

  • 1Zentrum für Hauttumoren, Südwestdeutsches Tumorzentrum, Universitätshautklinik Tübingen, Germany. thomas.eigentler@med.uni-tuebingen.de

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|November 2, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025
Same author

Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same journal

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral infections of the skin].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Viral exanthems in children].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Erratum to: Digital health applications and data protection].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Virus-induced exanthems in returning travellers].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
Same journal

[Venous ulcus cruris-Surgical treatment].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2022
See all related articles

Cutaneous melanoma (CM) incidence is rising, but mortality is stable. Key factors include UV exposure, pigmentation, and nevus count, with tumor thickness guiding prognosis and treatment.

Area of Science:

  • Dermatology and Oncology
  • Cutaneous Melanoma Research

Context:

  • Rising incidence of cutaneous melanoma (CM) globally.
  • Stabilized mortality rates despite increasing incidence.
  • Established risk factors: UV exposure, pigmentation, and melanocytic nevi.

Purpose:

  • To outline current understanding and management strategies for cutaneous melanoma.
  • To highlight prognostic indicators and treatment modalities.

Summary:

  • Vertical tumor thickness is the primary prognostic factor in CM.
  • Surgical excision with adequate margins is the standard treatment.
  • Sentinel lymph node biopsy is recommended for tumors ≥1.0 mm.
  • Interferon-alpha is the sole adjuvant therapy with proven benefit.

Related Experiment Videos

  • Palliative systemic treatment for metastatic CM includes dacarbazine.

    • Impact:

    • Informs clinical decision-making for CM diagnosis and treatment.
    • Provides a framework for patient follow-up based on disease parameters.
    • Contributes to improved outcomes and management of melanoma patients.